Global Gene Synthesis Service Market By Method (Solid-phase Synthesis, Chip-based Synthesis, and PCR-based Enzyme Synthesis), By Services (Antibody DNA Synthesis, Viral DNA Synthesis, and Others), By Application (Gene & Cell Therapy Development, Vaccine Development, Disease Diagnosis, and Others), By End-use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

The Global Gene Synthesis Service Market size is expected to be worth around US$ 16 Billion by 2034, from US$ 2.1 Billion in 2024, growing at a CAGR of 22.5% during the forecast period from 2025 to 2034.

The global gene synthesis service market is experiencing significant growth, driven by advancements in synthetic biology, increasing demand for personalized medicine, and rising investments in biotechnology research. Technological innovations have enhanced the efficiency and accuracy of gene synthesis, enabling the creation of custom DNA sequences for various applications, including gene therapy, vaccine development, and diagnostics. The growing focus on personalized medicine, which requires tailored genetic solutions for individual patients, is further fuelling the demand for gene synthesis services.

Additionally, substantial investments from governments and private institutions into genomics and synthetic biology are accelerating research and development in the field. However, the market faces challenges, including regulatory and ethical concerns surrounding synthetic DNA, as well as technical limitations in synthesizing long DNA sequences and successfully integrating them into functional biological systems. North America remains a key region in this market, benefiting from a well-established biotechnology infrastructure, significant research funding, and a concentration of major market players.

• In June 2024, GenScript Biotech Corporation was reported to have launched a new offering called the FLASH Gene service. This solution provides an accelerated sequence-to-plasmid (S2P) workflow, enabling the delivery of gene constructs within just four business days. It was noted for its flat-rate pricing structure starting at $89, which includes gene synthesis, cloning, and plasmid preparation. According to the company, the service ensures a guaranteed plasmid yield and 100% sequence accuracy. This rapid turnaround is expected to benefit researchers working in areas such as antibody drug development, vaccine production, and gene and cell therapy research.

• In November 2023, Twist Bioscience introduced a new service called Express Genes, designed to deliver rapid gene synthesis with a turnaround of just five to seven business days. Initially focused on small-scale gene synthesis, the service has since expanded to include midiprep (10μg to 100μg) and maxiprep (100μg to 1mg) DNA preparation options. According to industry reports, all Express Genes undergo next-generation sequencing (NGS) verification to ensure clonal perfection. This development is seen as a significant advancement for researchers across pharmaceutical, biotech, academic, and industrial chemical sectors, facilitating large-scale experimental applications with reliable DNA constructs.

Key Takeaways

• The global gene synthesis service market was valued at USD 2.1 billion in 2024 and is anticipated to register substantial growth of USD 16.0 billion by 2034, with 22.5% CAGR.
• In 2024, the solid-phase synthesis segment took the lead in the global market, securing 46.7% of the total revenue share.
• The antibody DNA synthesis segment took the lead in the global market, securing 60.4% of the total revenue share.
• The gene & cell therapy development segment took the lead in the global market, securing 36.2% of the total revenue share.
• The biotechnology & pharmaceutical companies segment took the lead in the global market, securing 52.4% of the total revenue share.
• North America maintained its leading position in the global market with a share of over 42.1% of the total revenue.

Method Analysis

In 2024, the solid-phase synthesis method held the largest share of 46.7% in the global gene synthesis service market. This dominance is attributed to its high efficiency, scalability, and accuracy in producing complex DNA sequences. The process involves attaching DNA to a solid support, enabling the stepwise addition of nucleotides with precision. This controlled approach ensures high-quality results and consistent sequence accuracy. Solid-phase synthesis is widely used in gene therapy, vaccine production, and synthetic biology due to its reliability and compatibility with complex genetic designs.

One major benefit of solid-phase synthesis is its ability to perform parallel synthesis. This enables the simultaneous construction of multiple gene sequences, significantly reducing overall production time. The technique is highly adaptable and supports both short and long DNA segments. Its suitability for diverse applications makes it a preferred choice in research and commercial use. As synthetic biology projects expand, this method continues to meet the industry’s growing need for fast and dependable gene synthesis.

Recent innovations have strengthened solid-phase synthesis. These include improved reagents, enhanced automation systems, and better error-checking processes. Such advancements have increased the technique’s efficiency and cost-effectiveness. Compared to other methods like liquid-phase or chip-based synthesis, solid-phase remains the gold standard. Its broad utility and technical advantages position it as a critical tool for future genetic engineering and personalized medicine.

Services Analysis

The global gene synthesis service market is fragmented by services into antibody DNA synthesis, viral DNA synthesis, and others. Among these, antibody DNA synthesis held the largest share of 60.4% in 2024. This dominance is attributed to its critical role in developing therapeutic antibodies, vaccines, and diagnostic tools. Antibody DNA synthesis involves creating DNA sequences that encode specific antibodies. These sequences are later expressed and purified for use in research and clinical applications. Its demand is rising, particularly in cancer immunotherapy and autoimmune disease treatment.

Antibody DNA synthesis provides high precision in designing antibodies with specific characteristics. These include improved binding affinity and targeted specificity, essential for drug development and disease treatment. The method is widely adopted in biopharmaceutical and diagnostic sectors. The growing reliance on monoclonal antibodies in clinical practice is a key factor boosting this segment. As healthcare trends shift toward personalized medicine, the need for accurate and efficient antibody design continues to expand.

• In April 2022, major advancements in this field were made with companies like Twist Bioscience Corporation and Codex DNA, Inc., which launched cutting-edge platforms for high-throughput antibody production. Twist Bioscience introduced a platform enabling customers to convert digital DNA sequences into purified IgG antibodies, streamlining the production process.
• In June 2022, Codex DNA was highlighted at the European Conference on Antibody Engineering and Therapeutics for presenting its advanced automated synthetic biology technologies. These innovations were showcased as part of efforts to streamline and accelerate antibody discovery workflows, demonstrating the company’s role in supporting faster and more efficient development of therapeutic antibodies.

These innovations reflect the increasing integration of digital technologies and automation in antibody synthesis, significantly enhancing the efficiency and scalability of antibody production. As demand for personalized medicine and targeted therapies continues to rise, antibody DNA synthesis is poised to remain a dominant segment in the gene synthesis market.

Application Analysis

The market is fragmented by application into gene & cell therapy development, vaccine development, disease diagnosis, and others. Gene & cell therapy dominated the global gene synthesis service market capturing a significant market share of 36.2% in 2024 owing to their transformative impact on treating genetic disorders and advancing personalized medicine. Gene synthesis services are essential for developing gene therapies, such as CRISPR-based treatments and viral vector systems, which require precise and custom-designed DNA sequences.

These services enable the creation of synthetic genes for therapeutic applications, including the development of CAR-T cells and other engineered cell therapies. The increasing prevalence of genetic diseases and cancers has intensified the demand for innovative treatments, further propelling the need for gene synthesis services. Moreover, advancements in gene-editing technologies and the growing focus on personalized medicine have expanded the scope of gene synthesis applications, encompassing areas such as vaccine development and genetic engineering.

The integration of gene synthesis with emerging technologies, such as CRISPR-Cas systems and synthetic biology, has enhanced the precision and efficiency of gene and cell therapies, making them more viable for clinical applications. As the field continues to evolve, gene synthesis services remain pivotal in enabling the development of next-generation therapies, thereby maintaining their dominant position in the market.​

End-use Analysis

The market is fragmented by end-use into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. Biotechnology & pharmaceutical companies dominated the global gene synthesis service market capturing a significant market share of 52.4% in 2024.

Biotechnology and pharmaceutical companies have been pivotal in driving the global gene synthesis service market, leveraging these services to advance research and therapeutic developments. These companies utilize gene synthesis to create custom DNA sequences for applications such as gene and cell therapy, vaccine development, and the production of monoclonal antibodies.

• For instance, biotechnology firms such as GenScript and Twist Bioscience offer gene synthesis services that support the development of gene therapies and biologics. Pharmaceutical companies, including major players like Novartis and Bristol-Myers Squibb, collaborate with gene synthesis providers to streamline their R&D processes and accelerate the development of targeted therapies.

The integration of gene synthesis into the drug discovery pipeline enables these companies to design and produce specific DNA sequences efficiently, facilitating the creation of novel therapeutics. Moreover, the increasing focus on personalized medicine and precision therapies has further amplified the demand for gene synthesis services, as customized DNA sequences are essential for tailoring treatments to individual patients. As a result, biotechnology and pharmaceutical companies continue to dominate the gene synthesis service market, driving innovation and expanding the applications of gene synthesis in medical research and treatment.​

Key Segments Analysis

By Method

• Solid-phase Synthesis
• Chip-based Synthesis
• PCR-based Enzyme Synthesis

By Services

• Antibody DNA Synthesis
• Viral DNA Synthesis
• Others

By Application

• Gene & Cell Therapy Development
• Vaccine Development
• Disease Diagnosis
• Others

By End-use

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Contract Research Organizations

Drivers

Increased Prevalence of Chronic Disorders

The increasing prevalence of chronic disorders is significantly driving the growth of the gene synthesis service market.

• In 2023, approximately 76.4% of U.S. adults reported having at least one chronic condition, with 51.4% experiencing multiple chronic conditions, highlighting a substantial burden on healthcare systems.

Chronic diseases such as heart disease, diabetes, and cancer necessitate ongoing research and development of targeted therapies, fuelling demand for precise gene synthesis services.

• For instance, chronic kidney disease affects about 14% of U.S. adults, underscoring the need for innovative treatments.

Gene synthesis enables the creation of custom DNA sequences for therapeutic applications, including gene and cell therapies, which are essential for addressing these chronic conditions. Moreover, the economic impact of chronic diseases, accounting for a significant portion of annual healthcare expenditures, further emphasizes the importance of advancing therapeutic solutions through gene synthesis. . As the prevalence of chronic disorders continues to rise, the demand for gene synthesis services is expected to expand, driving innovation in the development of personalized and effective treatments.​

Restraints

Lack of Skilled Professionals

The gene synthesis service market faces significant challenges due to a shortage of skilled professionals, which hampers its growth and development. Gene synthesis involves complex molecular biology techniques and requires a deep understanding of DNA manipulation, bioinformatics, and synthetic biology. The scarcity of trained experts in these areas leads to delays in project timelines, reduced efficiency, and increased risk of errors in synthesized DNA sequences. This shortage is particularly pronounced in emerging regions where educational and training facilities may be less developed.

• For instance, in 2022, a survey by the Biotechnology Innovation Organization (BIO) reported that nearly 47% of companies faced challenges in finding qualified personnel to support gene synthesis operations.

This talent gap constrains the market’s ability to meet the growing demand for gene synthesis services, especially in applications like gene therapy, vaccine development, and personalized medicine. To address this issue, there have been efforts to invest in education and training programs aimed at cultivating a new generation of skilled professionals.

For example, several universities in India and China launched specialized courses in 2023 to train students in advanced genetic engineering and synthetic biology. However, bridging the skill gap remains a critical challenge that requires sustained collaboration between academia, industry, and regulatory bodies to ensure a qualified workforce capable of supporting the expanding gene synthesis market.​

Opportunities

Escalated Adoption of Gene Therapy Technique in Molecular Biology

​The escalating adoption of gene therapy techniques in molecular biology is significantly driving the growth of the gene synthesis service market. Gene therapies, which involve modifying or manipulating genes to treat or prevent diseases, require precise and customized DNA sequences. Gene synthesis services facilitate the creation of these sequences, enabling the development of therapies for various genetic disorders.

• For instance, advancements in CRISPR-based gene editing have necessitated the synthesis of specific DNA sequences to correct genetic mutations.

The increasing prevalence of genetic diseases and the growing focus on personalized medicine further amplify the demand for gene synthesis services. Companies like ATUM and Integrated DNA Technologies are at the forefront, providing essential tools and services that support gene therapy research and development. As the field of gene therapy continues to expand, the need for accurate and efficient gene synthesis will remain pivotal, presenting substantial growth opportunities for the gene synthesis service market.​

Impact of macroeconomic factors / Geopolitical factors

​Macroeconomic and geopolitical factors significantly influence the gene synthesis service market, shaping its growth trajectory and operational dynamics. Macroeconomic conditions, such as inflation, exchange rates, and healthcare spending, directly affect the cost structures and pricing strategies of gene synthesis services. For instance, fluctuations in raw material costs can impact production expenses, while economic downturns may lead to reduced research budgets, affecting demand.

Conversely, increased government funding for genetic research projects can drive innovation and demand for gene synthesis services. US tariffs can significantly impact the gene synthesis service industry by potentially disrupting supply chains, increasing costs, and affecting international trade. These tariffs can contributes to higher prices for raw materials, reagents, and equipment, impacting both domestic and international providers of gene synthesis services.

Geopolitical factors also play a crucial role; trade policies and international relations can influence the global supply chain of raw materials and reagents essential for gene synthesis. Tensions or trade restrictions between countries may lead to shortages or increased costs of these materials. Additionally, geopolitical stability affects the establishment and operation of research facilities and collaborations across borders.

For example, regions with favorable trade agreements and stable political environments are more likely to attract investments in biotechnology research, thereby increasing the demand for gene synthesis services. Conversely, geopolitical instability can deter investment and disrupt research activities, leading to a slowdown in market growth. Therefore, both macroeconomic and geopolitical factors are integral in determining the operational landscape and growth prospects of the gene synthesis service market.​

Latest Trends

​The gene synthesis service market is experiencing several notable trends that are shaping its growth and development. Advancements in synthetic biology are driving demand for custom gene synthesis, enabling the creation of tailored genetic sequences for various applications, including gene therapy and vaccine development. The increasing focus on personalized medicine is propelling the need for precise synthetic genes that correspond to specific genotypes, facilitating the development of targeted treatments for complex diseases.

Technological innovations, such as the integration of artificial intelligence and automation in gene synthesis processes, are enhancing efficiency and accuracy, reducing errors, and expediting research outcomes. These innovations are particularly evident in the expansion of services such as Twist Bioscience’s Twist Express Genes, which offers rapid gene synthesis at all gene prep scales for researchers across different sectors.

Additionally, collaborations between companies, such as Elegen’s agreement with GSK to utilize its cell-free DNA manufacturing technology, are accelerating the development of vaccines and medicines. These trends indicate a dynamic and rapidly evolving gene synthesis service market, driven by technological advancements and an increasing emphasis on personalized and precision medicine.​

Regional Analysis

The North America gene synthesis service market is experiencing significant growth, driven by advancements in synthetic biology, increased demand for personalized medicine, and substantial investments in biotechnology research and development. Technological innovations, such as the integration of artificial intelligence and automation in gene synthesis processes, are enhancing efficiency and accuracy, reducing errors, and expediting research outcomes.

These innovations are particularly evident in the expansion of services such as Twist Bioscience’s Twist Express Genes, which offers rapid gene synthesis at all gene prep scales for researchers across different sectors. Furthermore, the increasing prevalence of chronic diseases, such as cardiovascular disorders and cancer, has intensified the demand for innovative treatments, further propelling the need for gene synthesis services.

Additionally, the growing focus on personalized therapeutics necessitates the synthesis of genes tailored to individual genetic profiles, thereby driving the demand for gene synthesis services. These trends indicate a dynamic and rapidly evolving gene synthesis service market in North America, driven by technological advancements and an increasing emphasis on personalized and precision medicine.​

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

​The gene synthesis service market is experiencing significant growth, with several key players leading the industry through innovation and strategic initiatives. Companies such as GenScript, Thermo Fisher Scientific, Integrated DNA Technologies, Eurofins Genomics, and Twist Bioscience are at the forefront, offering advanced gene synthesis services to meet the increasing demand in biotechnology and pharmaceutical research.

These organizations are expanding their service offerings, enhancing automation capabilities, and integrating artificial intelligence to improve efficiency and accuracy in gene synthesis processes. For instance, GenScript has introduced the Twist Express Genes platform, enabling rapid gene synthesis at various scales, catering to diverse research needs.

Additionally, Twist Bioscience has developed a silicon-based platform that allows for high-throughput DNA synthesis, significantly reducing costs and turnaround times. Strategic collaborations and partnerships are also common, as companies seek to enhance their technological capabilities and expand their market presence.

The competitive landscape is further influenced by regulatory developments, such as the U.S. government’s implementation of screening protocols for synthetic DNA to prevent misuse, which impacts operational practices within the industry. Overall, the market is characterized by rapid technological advancements, increased demand for customized genetic solutions, and a dynamic competitive environment.​

Top Key Players in the Gene Synthesis Service Market

• GenScript
• Brooks Automation Inc. (GENEWIZ)
• Boster Biological Technology
• Twist Bioscience
• ProteoGenix Inc.
• Biomatik
• ProMab Biotechnologies Inc.
• Thermo Fisher Scientific Inc.
• Integrated DNA Technologies Inc.
• OriGene Technologies Inc.

Recent Developments

• In February 2022: Integrated DNA Technologies (IDT) introduced Alt-R HDR Donor Blocks, a solution designed to enhance homology-directed repair (HDR) efficiency in large genomic insertions. These donor blocks are chemically modified to improve HDR rates and reduce non-homologous integrations, facilitating more precise genome editing.
• In April 2022: DNA Script launched an Early Access Program for advancements to its SYNTAX platform, which utilizes Enzymatic DNA Synthesis (EDS) technology. This program allows customers to develop DNA sequences with enhanced capabilities, including the synthesis of longer oligos and the incorporation of modifications such as fluorophores and biotin.

Report Scope